Show simple item record

dc.contributor.authorKitching, Michael
dc.contributor.authorMathur, Harsh
dc.contributor.authorFlynn, James
dc.contributor.authorByrne, Noel
dc.contributor.authorDillon, Pat
dc.contributor.authorSayers, Riona
dc.contributor.authorRea, Mary
dc.contributor.authorHill, Colin
dc.contributor.authorRoss, R. Paul
dc.date.accessioned2020-08-28T11:44:52Z
dc.date.available2020-08-28T11:44:52Z
dc.date.issued2019-09-27
dc.identifier.citationKitching M, Mathur H, Flynn J, Byrne N, Dillon P, Sayers R, Rea MC, Hill C and Ross RP (2019) A Live Bio-Therapeutic for Mastitis, Containing Lactococcus lactis DPC3147 With Comparable Efficacy to Antibiotic Treatment. Front. Microbiol. 10:2220. https://doi.org/10.3389/fmicb.2019.02220en_US
dc.identifier.issn1664-302X
dc.identifier.urihttp://hdl.handle.net/11019/2321
dc.descriptionpeer-revieweden_US
dc.description.abstractBovine mastitis is an ongoing significant concern in the dairy and agricultural industry resulting in substantial losses in milk production and revenue. Among the predominant etiological agents of bovine mastitis are Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, and Escherichia coli. Currently, the treatment of choice for bovine mastitis involves the use of commercial therapeutic antibiotic formulations such as TerrexineTM, containing both kanamycin and cephalexin. Such antibiotics are regularly administered in more than one dose resulting in the withholding of milk for processing for a number of days. Here, we describe the optimization of a formulation of Lactococcus lactis DPC3147, that produces the two-component bacteriocin lacticin 3147, in a liquid paraffin-based emulsion (formulation hereafter designated ‘live bio-therapeutic’) for the first time and compare it to the commercial antibiotic formulation TerrexineTM, with a view to treating cows with clinical/sub-clinical mastitis. Critically, in a field trial described here, this ‘ready-to-use’ emulsion containing live L. lactis DPC3147 cells exhibited comparable efficacy to TerrexineTM when used to treat mastitic cows. Furthermore, we found that the L. lactis cells within this novel emulsion-based formulation remained viable for up to 5 weeks, when stored at 4, 22, or 37◦C. The relative ease and cost-effective nature of producing this ‘live bio-therapeutic’ formulation, in addition to its enhanced shelf life compared to previous aqueous-based formulations, indicate that this product could be a viable alternative therapeutic option for bovine mastitis. Moreover, the singledose administration of this ‘live bio-therapeutic’ formulation is a further advantage, as it can expedite the return of the milk to the milk pool, in comparison to some commercial antibiotics. Overall, in this field trial, we show that the live bio-therapeutic formulation displayed a 47% cure rate compared to a 50% cure rate for a commercial antibiotic control, with respect to curing cows with clinical/sub-clinical mastitis. The study suggests that a larger field trial to further demonstrate efficacy is warranted.en_US
dc.language.isoenen_US
dc.publisherFrontiers Media SAen_US
dc.relation.ispartofseriesFrontiers in Microbiology;10
dc.rightsAttribution-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-sa/3.0/us/*
dc.subjectmastitisen_US
dc.subjectemulsionen_US
dc.subjectlacticin 3147en_US
dc.subjectsomatic cell counten_US
dc.subjectantibioticsen_US
dc.titleA Live Bio-Therapeutic for Mastitis, Containing Lactococcus lactis DPC3147 With Comparable Efficacy to Antibiotic Treatmenten_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3389/fmicb.2019.02220
dc.contributor.sponsorEnterprise Irelanden_US
dc.contributor.sponsorScience Foundation Irelanden_US
dc.contributor.sponsorGrantNumberCF/2015/0122Aen_US
dc.contributor.sponsorGrantNumberSFI/12/RC/2273en_US
dc.source.volume10
refterms.dateFOA2020-08-28T11:44:53Z


Files in this item

Thumbnail
Name:
fmicb-10-02220.pdf
Size:
1.556Mb
Format:
PDF
Description:
main article

This item appears in the following Collection(s)

Show simple item record

Attribution-ShareAlike 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-ShareAlike 3.0 United States